Securities code: 002821 securities abbreviation: Asymchem Laboratories (Tianjin) Co.Ltd(002821) Announcement No.: 2022-018 Asymchem Laboratories (Tianjin) Co.Ltd(002821) Pharmaceutical Group (Tianjin) Co., Ltd
Announcement on signing major contracts for daily operation
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and there are no false records, misleading statements or major omissions.
Special tips:
1. The contract takes effect upon the signature and seal of both parties. At present, the contract has taken effect.
2. During the performance of the contract, affected by the progress of new drug approval of customers, changes in demand, uncertainty of market environment, unpredictability or force majeure and other factors, there may be a risk that some contracts can not be fully performed. Please pay attention to investment risks.
3. If the contract is successfully performed and the delivery time is 2022, it is expected to have a positive impact on the company’s financial situation and operating results in 2022. The specific impact shall be subject to the audit report.
4. According to the relevant rules on information disclosure of major daily business contracts, those who have fulfilled the relevant information disclosure obligations in accordance with the provisions will not be included in the cumulative calculation range, and the company must only fulfill the corresponding information disclosure obligations of this contract. 1、 Contract signing overview
Asymchem Laboratories (Tianjin) Co.Ltd(002821) Pharmaceutical Group (Tianjin) Co., Ltd. (hereinafter referred to as “the company”) continues to provide contract customized R & D and production (cdmo) services for a small molecule chemical innovative drug of a pharmaceutical company (hereinafter referred to as “the customer”), Recently, Jilin Asymchem Laboratories (Tianjin) Co.Ltd(002821) Pharmaceutical Chemistry Co., Ltd., a wholly-owned subsidiary of the company, signed a new batch of supply contract for related products with customers. The contract amount is equivalent to about 3.542 billion yuan. The new supply contract has come into force after being signed and sealed by both parties.
2、 Introduction to counterparty
Therefore, this transaction involves keeping trade secrets. According to the relevant agreements signed between the company and customers, the basic information of the counterparty and product related information are not disclosed.
There is no relationship between the counterparty and the company this time.
The counterparty is a pharmaceutical company with good credit and good performance ability. The company has maintained a sustained and good cooperative relationship with the counterparty for a long time.
3、 Main contents of signing the contract
1. Contract type: supply contract
2. Total contract amount: about 3.542 billion yuan
3. Conditions and time of effectiveness of the contract: the contract shall come into force after being signed and sealed by both parties
4. Performance period of the contract: the supply time of the contract is 2022
Others: the terms of the contract have made clear provisions on the terms of payment, quality assurance, quality supervision, inspection and acceptance, technical services, contract change and termination, liability for breach of contract and handling of contract disputes. 4、 The impact of contracts on Listed Companies
1. The total amount of the contract is about RMB 3.542 billion. The performance of the contract will have a positive impact on the company’s operating revenue and operating profit in 2022. The company will recognize the revenue in the corresponding accounting period according to the performance obligations of the contract and the revenue recognition principle. The company will continuously disclose the performance of the contract in regular reports in accordance with relevant disclosure regulations.
2. The performance of this contract will not affect the business independence of the company, and the main business of the company will not rely on the parties due to the performance of the contract.
3. The company has the ability to perform the contract, and the capital, personnel, technology and production capacity can ensure the smooth performance of the above contract. The performance of the above contracts will have a positive impact on the company’s future profits.
4. As a world leading cdmo one-stop comprehensive service provider serving the R & D and production of new drugs, the company has nearly 20 years of customer reputation and technical experience. Through providing one-stop CMC service, efficient and high-quality R & D and production services for pharmaceutical companies and biotechnology companies at home and abroad, Accelerate the clinical research and commercial application of innovative drugs. This supply contract is a further cooperation between the two parties to further consolidate and prove the company’s comprehensive competitive advantage in small molecule cdmo industry.
5、 Contract risk tips
During the execution of this contract, the company basically has no risks in terms of performance capacity, technology and production capacity. Due to the changes of customer demand, uncertainty of market environment, unpredictable or force majeure and other factors, there may be the risk that some contracts can not be fully performed. Please pay attention to the investment risk.
6、 Documents for future reference
Supply contract and confidentiality agreement signed with customers.
It is hereby announced.
Board of directors of Pharmaceutical Group (Tianjin) Co., Ltd. February 21, 2002
